MedTrace Logo

The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients

NCT01273974 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2011-01-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether half-dose intradermal influenza vaccine is as immunogenic as standard dose intramuscular vaccine in hemodialysis patients.

Conditions

  • Hemodialysis Patients

Interventions

BIOLOGICAL

intradermal influenza vaccine

0.25ml ,intradermal

BIOLOGICAL

intramuscular influenza vaccine

0.5ml,intramuscular

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammad mahdi Sagheb · Shiraz University Of Medical Science

  • Samira Saeian · Shiraz University Of Medical Science

  • Jamshid Roozbeh · Shiraz University Of Medical Science

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2009-11-30
Completion
2010-02-28

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01273974 on ClinicalTrials.gov